{"symbol":"GILD","fiscalQuarter":"Q3-2022","reportDate":"2022-10-27","reportTime":"AMC","status":"reported","company":{"name":"Gilead Sciences, Inc.","sector":"Health Care","industry":"Biotechnology"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/GILD/earnings/Q3-2022","postBrief":{"headline":"Gilead Sciences Beats on EPS, Stock Down N/A%","keyNumbers":[{"metric":"EPS","actual":"$1.90","expected":"N/A","surprise":"+31.76%"},{"metric":"Revenue","actual":"N/A","expected":"N/A","surprise":"N/A"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["Management highlighted the strong performance in their antiviral portfolio.","They noted ongoing challenges in the market but expressed confidence in future product launches."],"summary":"Overall, management conveyed a sense of cautious optimism regarding their product pipeline. They acknowledged market challenges but emphasized their commitment to innovation."},"guidanceChanges":{"summary":"No guidance was provided during the earnings call.","changes":[]},"whatItMeans":"Gilead Sciences reported a strong earnings per share, exceeding expectations significantly. However, the lack of revenue data and guidance may leave investors uncertain about the company's future performance. The stock reaction is not available, but the strong EPS could indicate positive momentum in their business operations.","metaDescription":"Gilead Sciences (GILD) Q3 2022 earnings: EPS beat by 31.76%. Stock reaction not available. Full breakdown."}}